Preventing HIV Infection

The Food and Drug administration approved a drug, Truvada,  to reduce the chances of HIV infection.   This just after the first HIV home test was approved by the FDA. HIV infections in the United States hold steady at about 50,000 new cases per year.  Currently there are 1.2 million Americans with HIV, which  develops into AIDS unless treated. It is hoped this drug will reduce the number of new cases.

The use of Truvada is called preexposure prophylaxis, and is used to prevent HIV infection from partners of HIV infected individuals.  Preexposure prophylaxis had been limited to the use of condoms.  It is hoped that intervention with Truvada, and possibly other drugs, will provides major step toward reducing HIV infections in the United States.  The drug is effective to reduce transmission by as much as 75% in heterosexual and gay couples.  Another study whosed that daily doses cut the risk of infection in healthy gay and bisexual men by 42% when used with condoms and counseling. In another study Truvada reduced the infection rate in heterosexual couples when one partner was infected.

The drug is Truvada, a combination of two anti-viral drugs tenofovir and emtricitabine.  Truvada has been used, in combination with other drugs, for patients who have HIV but is not effective used alone.

The results from the study varied widely, from 40% to 75%, and while some could be explained by adherence to the daily regimen of the drug, there were clearly roles for other factors.  The drug must be taken daily, and cannot be skipped, and the partners must use condoms with sexual activity.  During one of the studies there was a high rate of pregnancy, indicating that unprotected intercourse was more common than self-reported.

Before prescribing the drug, the patient must be confirmed to be HIV negative. This was not made a requirement by the FDA.  A patient who has HIV and uses this drug has ineffective treatment for HIV, which requires three anti-viral medications, and the concern would be that if an HIV positive patient uses this drug they may develop a resistance to this medication.

The drug is not risk free and there was noted changes in kidney and liver function as well as reduced bone density. Side effects include diarrhea, nausea, abdominal pain, headache, and weight loss.  The FDA will continue to monitor the drug for adverse events.  The other concern is that Truvada will lead to unprotected sex. In addition, there is no data regarding the use of Truvada in pregnancy

The drug is costs about $13,000 per year, and there is no word if insurance will cover the use of the drug.

We still await, however, a vaccine against HIV.

Dr. Terry Simpson About Dr. Terry Simpson
Dr. Terry Simpson received his undergraduate and graduate degrees from the University of Chicago where he spent several years in the Kovler Viral Oncology laboratories doing genetic engineering. He found he liked people more than petri dishes, and went to medical school. Dr. Simpson, a weight loss surgeon is an advocate of culinary medicine. The first surgeon to become certified in Culinary Medicine, he believes teaching people to improve their health through their food and in their kitchen. On the other side of the world, he has been a leading advocate of changing health care to make it more "relationship based," and his efforts awarded his team the Malcolm Baldrige award for healthcare in 2011 for the NUKA system of care in Alaska and in 2013 Dr Simpson won the National Indian Health Board Area Impact Award. A frequent contributor to media outlets discussing health related topics and advances in medicine, he is also a proud dad, husband, author, cook, and surgeon “in that order.” For media inquiries, please visit www.terrysimpson.com.

Share this article on social media!

Latest Comments

  1. gold account says:

    The overall declines in new HIV infections among IDUs since the 1980s likely are related to decreases in injection-drug use or the sharing of injection equipment and changes in social networks of IDUs (e.g., associating with persons who do not have HIV infection or who are less likely to share injecting equipment) ( 9 ). However, many IDUs with newly diagnosed infection have suboptimal access to and utilization of highly active antiretroviral therapy (HAART), and initiate HAART at more advanced stages of infection (10). Programs to prevent HIV among IDUs should address both risk from injecting and risk from unsafe sexual behavior. HIV testing should be a key component of any comprehensive strategy, and new opportunities to test IDUs (e.g., in correctional facilities or mental health clinics) should be considered. In addition, newer testing technologies such as rapid HIV testing might enable programs to reach IDUs who would otherwise not be tested.

  2. Lynn says:

    There was a pro and con article in US News and World report and one con is that studies show that the majority of people on prescription medication, do indeed skip doses. Human behavior dictates that this drug would probably not be effective.

Leave a Reply